Thijn Brummelkamp
co-founder
Pediatric
Haplogen
Austria
Biography
Dr Brummelkamp received his PhD from the Netherlands Cancer Institute and was appointed as a Fellow in 2004 at the Whitehead Institute for Biomedical Research in Cambridge in the United States. He was listed among the world's top innovators under the age of 35 by M.I.T.'s Technology Review Magazine (2005) and was awarded the prestigious EMBO Gold Medal (2013). Currently, he is a group leader at the Netherlands Cancer Institute and adjunct Principal Investigator at CeMM. Thijn Brummelkamp developed the haploid genetics technology that forms the technology basis of Haplogen. Dr Brummelkamp received his PhD from the Netherlands Cancer Institute and was appointed as a Fellow in 2004 at the Whitehead Institute for Biomedical Research in Cambridge in the United States. He was listed among the world's top innovators under the age of 35 by M.I.T.'s Technology Review Magazine (2005) and was awarded the prestigious EMBO Gold Medal (2013). Currently, he is a group leader at the Netherlands Cancer Institute and adjunct Principal Investigator at CeMM. Thijn Brummelkamp developed the haploid genetics technology that forms the technology basis of Haplogen.
Research Interest
Pediatric Cardiology, Pediatric Neurology & Diseases, Pediatric & Neonatal Care
